Biodexa Pharmaceuticals PLC (BDRX) has a current Price-to-Book (P/B) ratio of 0.10. Compared to its 3-year average P/B ratio of 0.60, the current P/B ratio is approximately -83.56% higher. Relative to its 5-year average P/B ratio of 0.35, the current P/B ratio is about -71.79% higher. Biodexa Pharmaceuticals PLC (BDRX) has a Forward Free Cash Flow (FCF) yield of approximately -864.05%. Compared to its 3-year average FCF yield of -341.26%, the current FCF yield is approximately 153.19% lower. Relative to its 5-year average FCF yield of -232.09%, the current FCF yield is about 272.29% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BDRX competitors is 1.07, providing a benchmark for relative valuation. Biodexa Pharmaceuticals PLC Corp (BDRX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BDRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BDRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BDRX currently overvalued or undervalued?

What is Biodexa Pharmaceuticals PLC (BDRX) fair value?

BDRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Biodexa Pharmaceuticals PLC (BDRX) is between NaN to NaN according to relative valuation method.

How does BDRX's valuation metrics compare to the industry average?

The average P/S ratio for BDRX's competitors is 1.07, providing a benchmark for relative valuation. Biodexa Pharmaceuticals PLC Corp (BDRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Biodexa Pharmaceuticals PLC (BDRX) as of Mar 03 2026?

As of Mar 03 2026, Biodexa Pharmaceuticals PLC (BDRX) has a P/B ratio of 0.10. This indicates that the market values BDRX at 0.10 times its book value.

What is the current FCF Yield for Biodexa Pharmaceuticals PLC (BDRX) as of Mar 03 2026?

As of Mar 03 2026, Biodexa Pharmaceuticals PLC (BDRX) has a FCF Yield of -864.05%. This means that for every dollar of Biodexa Pharmaceuticals PLC's market capitalization, the company generates -864.05 cents in free cash flow.

What is the current Forward P/E ratio for Biodexa Pharmaceuticals PLC (BDRX) as of Mar 03 2026?

As of Mar 03 2026, Biodexa Pharmaceuticals PLC (BDRX) has a Forward P/E ratio of -7.31. This means the market is willing to pay $-7.31 for every dollar of Biodexa Pharmaceuticals PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Biodexa Pharmaceuticals PLC (BDRX) as of Mar 03 2026?

As of Mar 03 2026, Biodexa Pharmaceuticals PLC (BDRX) has a Forward P/S ratio of 0.00. This means the market is valuing BDRX at $0.00 for every dollar of expected revenue over the next 12 months.

BDRX Valuation